The Alinea Group understands the importance of implementing a compliant 340B program. Building on a defined methodology that was developed using first-hand experience with HRSA, drug manufacturer, and State Medicaid 340B compliance audits, our approach is focused on identifying and providing the necessary guidance to prepare our clients for future audits.
Healthcare, Pharmacy, and 340B Websites
Health Resources Services Administration
Read a statement from the Health Resources and Services Administration Regarding Recent Court Rulings Involving the 340B Program.
Healthcare Revenue Cycle
The editors at RevCycleIntelligence, part of the Xtelligent Healthcare Media network, connect with health systems, hospitals, and physician groups to share their firsthand experience managing claims, improving A/R management and performance, and adopting new models of reimbursement impacting the financial health of their organizations.
Latest clinical news from MJH Life Sciences. For over 20 years, MJH Life Sciences™ has been dedicated to providing health care professionals with the trusted information, resources, and education they need to optimize patient outcomes and improve care.
340B Health is a membership organization of more than 1,400 public and private nonprofit hospitals and health systems participating in the federal 340B drug pricing program. To support their members, 340B Health monitors, educates, and serves as an advocate on federal legislative and regulatory issues related to drug pricing and other matters affecting safety-net providers.
Office of Pharmacy Affairs
In accordance with Section 340B(d)(1)(B) of the Public Health Service Act, HRSA is required to collect information from manufacturers to verify the accuracy of 340B ceiling prices, and then make ceiling prices available to covered entities. To this end, HRSA has developed a new, integrated information system that focuses on three key priorities: security, user accessibility, and data accuracy.
Healthcare Finance is the leading news source for developments in the healthcare finance industry. Through its highly integrated platform, its team of award-winning editors deliver breaking news, in-depth reporting, analysis and best practices around compelling topics such as capital investments, reimbursements, quality and safety, physician relations, billing collections a data integrity and how they affect both providers and payers alike.
Modern Healthcare is the industry’s leading source of healthcare business and policy news, research and information. They report on important healthcare events and trends, as they happen, through print magazine, websites, e-newsletters, mobile products and events.
340B Report is the indispensable source of independent, comprehensive news coverage and analysis of the federal 340B drug discount program. We follow all 340B program developments big and small—in federal government agencies, Congress, courts, the states, associations, the private sector, academia, and more.
Three 340B Predictions for the New Year
It’s the New Year which means new conversation and perspective on how federal policy will impact 340B regulation and providers in the coming months. As a friend of the 340B Report, we found its Publisher Ted Slafsky’s recent insight on the Omnicell blog worth a read.
As Big Pharma and Hospitals Battle Over Drug Discounts, Patients Miss Out on Millions in Benefits
Labette Health, located in Parsons, Kansas, uses its 340B earnings to operate rural health clinics. The leadership at the hospital, which is one of the few still open in the region, says it has lost more than a million dollars in revenue over the past year due to pharmaceutical companies restricting the use of contract pharmacies.
Drug Price Transparency Laws Position States to Impact Drug Prices
Drug price transparency laws enable state policymakers to understand opaque drug pricing and payment systems to formulate appropriate policy solutions to high prices, while also creating the data infrastructure to effectively realize those policy solutions. Since Vermont passed the first state drug price transparency law in 2016, more than a dozen states have enacted and implemented similar laws.
CMS Releases Medicare Advantage and Part D Proposed Rule
King & Spalding shares a high-level summary of certain significant changes in the Proposed Rule CMS recently published. The Proposed Rule would revise Medicare Advantage (Part C) and Medicare Prescription Drug Benefit (Part D) regulations.
Amazon Must Reads
Best Sellers in Hospital Administration & Care.